Navigation Links
Actinobac Biomed, Inc. Demonstrates In Vivo Efficacy for Psoriasis Treatment
Date:6/14/2011

NEW BRUNSWICK, N.J., June 14, 2011 /PRNewswire-USNewswire/ -- Psoriasis is a persistent, long-lasting chronic skin disease affecting 2-3 percent of the world's population or more than 125 million individuals.  For some, it is just a nuisance. For others, it is disabling.

On a continuing quest to find more effective treatment for psoriasis sufferers, an article published in the Journal of Investigative Dermatology reported that the latest data from experiments performed by Actinobac Biomed, Inc., with financial backing from Foundation Venture Capital Group, LLC, successfully demonstrated the in vivo efficacy of the company's drug candidate, Leukothera™, in treating psoriasis in a humanized mouse xenograft transplantation model.  (http://www.nature.com/jid/journal/vaop/ncurrent/abs/jid2011161a.html)

"Our results clearly show that the idea of depleting diseased white blood cells with Leukothera™ is a highly effective strategy for the treatment of psoriasis and other inflammatory diseases," said Dr. Scott Kachlany, Actinobac's founder.

The studies performed at Aarhus University Hospital in Denmark showed Leukothera™ to be as effective as or better than Genentech's once marketed agent, efalizumab (Raptiva®), even when using significantly lower drug dosage levels.  Leukothera™ is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.  

"We provided early seed funding to Actinobac because we are convinced that they are working on breakthrough research that will make a huge impact to thousands and thousands of people around the world suffering from a variety of ailments," said James M. Golubieski, president of Foundation Venture Capital Group (www.foundationventure.com), an affiliate of New Jersey Health Foundation.  "The publication of Dr. Kachlany's findings relative to the treatment of psoriasis is proof of that."

Actinobac Biomed, Inc. was founded in 2009 to develop commercial products based upon technology developed at the University of Medicine and Dentistry of New Jersey.  The company has exclusively licensed the rights to develop Leukothera™ as a therapeutic agent.

The current focus of Actinobac activities involves the development of pharmaceutical technologies based upon the natural biologic agent leukotoxin (Leukothera™), which targets Leukocyte Function Antigen-1 (LFA-1) on diseased white blood cells.  For the work in psoriasis and other autoimmune/inflammatory diseases, Actinobac plans to continue IND-enabling studies to test in humans shortly.

For more information or to explore ways in which to partner with Actinobac, contact them at 732-371-2694, info@actinobac.com, or visit www.actinobac.com.


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Prototype demonstrates success of advanced new energy technology
2. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
3. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
4. New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care
5. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
6. Dune Medicals MarginProbe™ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
7. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
8. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
9. Capasso lab demonstrates highly unidirectional whispering gallery microlasers
10. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
11. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... compliance training, today announced an interactive FDA compliance training course, ... (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> --> Fourth ... (105.0), up 1,187% compared with fourth quarter of 2014. Gross ... M (loss: 30.0). Earnings per share increased to SEK 6.39 ... M (neg: 74.7). , --> ... SEK 2,900.5 M (233.6), up 1,142% compared with 2014. Gross ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
Breaking Biology News(10 mins):